Most cited papers from Chimerix (United States)

Chimerix (United States)

What are the most cited papers from Chimerix (United States)?

The most cited paper from Chimerix (United States) is "Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1." (Per T Ljungman, Michael Boeckh, Hans Hellmuth Hirsch et al., 2016), with 966 citations. Next come "CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation" (374) and "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial" (298).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 27 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1. Per T Ljungman, Michael Boeckh, Hans Hellmuth Hirsch et al. · Clinical Infectious Diseases	28 Sep 2016	966
2	CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation Francisco M. Marty, Drew J. Winston, Scott D. Rowley et al. · New England Journal of Medicine Open access	25 Sep 2013	374
3	Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Kris V. Kowdley, Eric Lawitz, Israel Crespo et al. · The Lancet	15 Mar 2013	298
4	Efficacy of transfusion with granulocytes from G-CSF/dexamethasone–treated donors in neutropenic patients with infection Thomas H. Price, Michael Boeckh, Ryan W. Harrison et al. · Blood Open access	2 Sep 2015	254
5	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation Francisco M. Marty, Drew J. Winston, Roy F. Chemaly et al. · Transplantation and Cellular Therapy Open access	4 Oct 2018	220
6	Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model Christina L. Hutson, Ashley V. Kondas, Matthew R. Mauldin et al. · mSphere Open access	16 Feb 2021	177
7	The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality Joshua Aiden Hill, Bryan T. Mayer, Hu Xie et al. · Blood Open access	17 Feb 2017	177
8	First Pharmacokinetic and Safety Study in Humans of the Novel Lipid Antiviral Conjugate CMX001, a Broad-Spectrum Oral Drug Active against Double-Stranded DNA Viruses Wendy Painter, Alice T. Robertson, Lawrence C. Trost et al. · Antimicrobial Agents and Chemotherapy Open access	6 Mar 2012	177
9	Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney Stephanie L. Ciesla, Julissa Trahan, William Wan et al. · Antiviral Research	30 Jun 2003	177
10	Safety and Efficacy of CMX001 as Salvage Therapy for Severe Adenovirus Infections in Immunocompromised Patients Diana F. Florescu, Steven A. Pergam, Michael Noel Neely et al. · Transplantation and Cellular Therapy Open access	29 Sep 2011	176
11	Development of CMX001 for the Treatment of Poxvirus Infections Randall Lanier, Lawrence C. Trost, Tim Tippin et al. · Viruses Open access	17 Dec 2010	166
12	Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial Michael S. Grimley, Roy F. Chemaly, Janet A. Englund et al. · Transplantation and Cellular Therapy Open access	6 Jan 2017	164
13	Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Sriram Venneti et al. · Cancer Discovery Open access	11 Aug 2023	162
14	Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model Károly Tóth, Jacqueline F. Spencer, Debanjan Dhar et al. · Proceedings of the National Academy of Sciences Open access	19 May 2008	153
15	Synergistic Efficacy of the Combination of ST-246 with CMX001 against Orthopoxviruses Debra C. Quenelle, Mark N. Prichard, Kathy A. Keith et al. · Antimicrobial Agents and Chemotherapy Open access	28 Aug 2007	141
16	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma Evan Cantor et al. · Neuro-Oncology Open access	4 Feb 2022	130
17	Short-term clinical safety profile of brincidofovir: A favorable benefit–risk proposition in the treatment of smallpox Greg Chittick, Marion E. Morrison, Thomas M. Brundage et al. · Antiviral Research	14 Jan 2017	130
18	Progressive Vaccinia: Case Description and Laboratory-Guided Therapy With Vaccinia Immune Globulin, ST-246, and CMX001 Edith R. Lederman, Whitni Davidson, Harold L. Groff et al. · The Journal of Infectious Diseases Open access	16 Aug 2012	125
19	ONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline Glioma Isabel Arrillaga‐Romany et al. · Journal of Clinical Oncology Open access	9 Feb 2024	112
20	Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model Scott Parker, Erin Touchette, Christina Oberle et al. · Antiviral Research Open access	5 Sep 2007	105
21	Leveraging external data in the design and analysis of clinical trials in neuro-oncology Rifaquat M. Rahman, Steffen Ventz, Jon McDunn et al. · The Lancet Oncology Open access	27 Sep 2021	90
22	Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001 Kris Paolino, Jane E. Sande, Evelio D. Perez‐Albuerne et al. · Journal of Clinical Virology	20 Nov 2010	86
23	Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation Joshua Aiden Hill, Bryan T. Mayer, Hu Xie et al. · Clinical Infectious Diseases Open access	7 Sep 2017	82
24	Design and development of oral drugs for the prophylaxis and treatment of smallpox infection George R. Painter, Karl Y. Hostetler · Trends in biotechnology Review	6 Jul 2004	80
25	Incidence of Adenovirus Infection in Hematopoietic Stem Cell Transplantation Recipients: Findings from the AdVance Study Petr Sedláček, Toni Petterson, Marie Robin et al. · Transplantation and Cellular Therapy Open access	19 Dec 2018	79
26	Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors Matthew J. Mosquera et al. · Advanced Materials Open access	22 Oct 2021	77
27	Efficacy of CMX001 against Herpes Simplex Virus Infections in Mice and Correlations with Drug Distribution Studies Debra C. Quenelle, Bernhardt Lampert, Deborah J. Collins et al. · The Journal of Infectious Diseases Open access	5 Oct 2010	76
28	Brincidofovir Is Not a Substrate for the Human Organic Anion Transporter 1: A Mechanistic Explanation for the Lack of Nephrotoxicity Observed in Clinical Studies Timothy K. Tippin, Marion E. Morrison, Thomas M. Brundage et al. · Therapeutic Drug Monitoring Open access	16 Nov 2016	74
29	Evaluation of Hexadecyloxypropyl-9- R -[2-(Phosphonomethoxy)Propyl]- Adenine, CMX157, as a Potential Treatment for Human Immunodeficiency Virus Type 1 and Hepatitis B Virus Infections George R. Painter, Merrick R. Almond, Lawrence C. Trost et al. · Antimicrobial Agents and Chemotherapy Open access	24 Jul 2007	73
30	Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans Amanda D. Rice, Mathew M. Adams, Greg Wallace et al. · Viruses Open access	24 Jan 2011	71
31	ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma Isabel Arrillaga‐Romany, Andrew B. Lassman, Susan Lynne McGovern et al. · Neuro-Oncology Open access	5 Mar 2024	69
32	Brincidofovir for Polyomavirus-Associated Nephropathy After Allogeneic Hematopoietic Stem Cell Transplantation Genovefa A. Papanicolaou, Yeon Joo Lee, James W. Young et al. · American Journal of Kidney Diseases Open access	16 Jan 2015	64
33	In Vitro Efficacy of Brincidofovir against Variola Virus Victoria A. Olson, Scott K. Smith, Scott A. Foster et al. · Antimicrobial Agents and Chemotherapy Open access	24 Jun 2014	63
34	Presentation of BK polyomavirus–associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation Hannah N. Imlay, Hu Xie, Wendy M. Leisenring et al. · Blood Advances Open access	19 Feb 2020	61
35	Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy Sharon L. Gardner et al. · Neuro-Oncology Advances Open access	2022	60
36	CMX001 Potentiates the Efficacy of Acyclovir in Herpes Simplex Virus Infections Mark N. Prichard, Earl R. Kern, Caroll B. Hartline et al. · Antimicrobial Agents and Chemotherapy Open access	26 Jul 2011	59
37	The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: A model of smallpox disease Lawrence C. Trost, Michelle Rose, Jody M. Khouri et al. · Antiviral Research Open access	4 Mar 2015	58
38	Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans Amanda D. Rice, Mathew M. Adams, Bernhard M. Lampert et al. · Viruses Open access	25 Jan 2011	54
39	Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox – An animal model of smallpox Scott Parker, Nanhai G. Chen, Scott A. Foster et al. · Antiviral Research Open access	18 Feb 2012	54
40	Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus Jeffrey M. Chamberlain, Katherine Sortino, Phiroze B. Sethna et al. · Antimicrobial Agents and Chemotherapy Open access	20 Dec 2018	52
41	The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus Laura K. McMullan, Mike Flint, Julie Dyall et al. · Antiviral Research	25 Oct 2015	52
42	Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside/Nucleotide-Resistant HIV E. Randall Lanier, Roger G. Ptak, Bernhard M. Lampert et al. · Antimicrobial Agents and Chemotherapy Open access	4 May 2010	47
43	H3K27M mutant glioma: Disease definition and biological underpinnings Amanda Muhs Saratsis, Truman Knowles, Antonela Petrović et al. · Neuro-Oncology Open access	11 Oct 2023	42
44	Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D2 Dopamine Receptor R. Benjamin Free, Caroline A. Cuoco, Bing Xie et al. · Molecular Pharmacology Open access	5 Aug 2021	42
45	Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits Irma M. Grossi, Scott A. Foster, Melicia R. Gainey et al. · Antiviral Research	7 Apr 2017	40
46	Biochemical and Mechanistic Basis for the Activity of Nucleoside Analogue Inhibitors of HIV Reverse Transcriptase George R. Painter, Merrick R. Almond, Shuli Mao et al. · Current Topics in Medicinal Chemistry	Jun 2004	39
47	Discovery of Macrocyclic Pyrimidines as MerTK‐Specific Inhibitors Andrew L. McIver, Weihe Zhang, Qingyang Liu et al. · ChemMedChem Open access	28 Dec 2016	38
48	Brincidofovir for Prevention of Cytomegalovirus (CMV) after Allogeneic Hematopoietic Cell Transplantation (HCT) in CMV-Seropositive Patients: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Trial Francisco M. Marty, Drew J. Winston, Roy F. Chemaly et al. · Transplantation and Cellular Therapy Open access	18 Feb 2016	38
49	Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance Sunwen Chou, Ronald J. Ercolani, E. Randall Lanier · Antimicrobial Agents and Chemotherapy Open access	5 Apr 2016	36
50	Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus Scott H. James, Nathan B. Price, Caroll B. Hartline et al. · Antimicrobial Agents and Chemotherapy Open access	7 May 2013	36

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.